이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Outlook Therapeutics 미래 성장

Future 기준 확인 5/6

Outlook Therapeutics은 연간 수입과 매출이 각각 67.5%와 69.7% 증가할 것으로 예상되고 EPS는 연간 74.4%만큼 증가할 것으로 예상됩니다.

주요 정보

67.5%

수익 성장률

74.4%

EPS 성장률

Biotechs 수익 성장	24.1%
매출 성장률	69.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	28 May 2024

최근 미래 성장 업데이트

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

수익 및 매출 성장 예측

NasdaqCM:OTLK - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2026	61	-26	N/A	N/A	4
9/30/2025	10	-64	N/A	-58	6
9/30/2024	N/A	-121	N/A	-66	7
3/31/2024	N/A	-159	-58	-58	N/A
12/31/2023	N/A	-51	-47	-47	N/A
9/30/2023	N/A	-59	-43	-43	N/A
6/30/2023	N/A	-60	-40	-40	N/A
3/31/2023	N/A	-57	-48	-48	N/A
12/31/2022	N/A	-70	-55	-55	N/A
9/30/2022	N/A	-66	-57	-57	N/A
6/30/2022	N/A	-65	-55	-55	N/A
3/31/2022	N/A	-60	-55	-55	N/A
12/31/2021	N/A	-53	-52	-52	N/A
9/30/2021	N/A	-53	-54	-54	N/A
6/30/2021	N/A	-50	-57	-57	N/A
3/31/2021	N/A	-40	-43	-43	N/A
12/31/2020	N/A	-45	-38	-38	N/A
9/30/2020	N/A	-49	-32	-32	N/A
6/30/2020	6	-49	-26	-26	N/A
3/31/2020	6	-51	-30	-30	N/A
12/31/2019	7	-45	-29	-29	N/A
9/30/2019	8	-36	-33	-32	N/A
6/30/2019	3	-38	-36	-35	N/A
3/31/2019	3	-43	-35	-33	N/A
12/31/2018	3	-40	-36	-34	N/A
9/30/2018	3	-48	-36	-33	N/A
6/30/2018	5	-43	-26	-25	N/A
3/31/2018	5	-39	-23	-22	N/A
12/31/2017	4	-39	N/A	-18	N/A
9/30/2017	4	-40	N/A	-16	N/A
6/30/2017	1	-43	N/A	-26	N/A
3/31/2017	2	-68	N/A	-36	N/A
12/31/2016	2	-64	N/A	-39	N/A
9/30/2016	3	-63	N/A	-45	N/A
6/30/2016	3	-71	N/A	-46	N/A
3/31/2016	4	-53	N/A	-40	N/A
12/31/2015	3	-64	N/A	-36	N/A
9/30/2015	5	-53	N/A	-27	N/A
9/30/2014	9	-21	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: OTLK 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.4% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: OTLK (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: OTLK 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: OTLK 의 수익(연간 69.7% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: OTLK 의 수익(연간 69.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: OTLK 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Outlook Therapeutics 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 13% to US$38.50

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Forecast breakeven date pushed back to 2026

Consensus revenue estimates decrease by 92%, EPS upgraded

Consensus revenue estimates decrease by 33%

Recent updates

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Price target decreased to US$6.58

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought US$257k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics: Likely FDA Approval, Possible Buyout

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial